PMID- 37550204
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20231106
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 44
IP  - 6
DP  - 2023 Jun 14
TI  - [Efficacy and safefy of Polymyxin B treatment for neutropenic patients suffering 
      from refractory Gram-negative bacterial bloodstream infection].
PG  - 484-489
LID - 10.3760/cma.j.issn.0253-2727.2023.06.007 [doi]
AB  - Objective: To assess the efficacy and safety of polymyxin B in neutropenic 
      patients with hematologic disorders who had refractory gram-negative bacterial 
      bloodstream infection. Methods: From August 2021 to July 2022, we retrospectively 
      analyzed neutropenic patients with refractory gram-negative bacterial bloodstream 
      infection who were treated with polymyxin B in the Department of Hematology of 
      the First Affiliated Hospital of the Soochow University between August 2021 to 
      July 2022. The cumulative response rate was then computed. Results: The study 
      included 27 neutropenic patients with refractory gram-negative bacterial 
      bloodstream infections. Polymyxin B therapy was effective in 22 of 27 patients. 
      The median time between the onset of fever and the delivery of polymyxin B was 3 
      days [interquartile range (IQR) : 2-5]. The median duration of polymyxin B 
      treatment was 7 days (IQR: 5-11). Polymyxin B therapy had a median antipyretic 
      time of 37 h (IQR: 32-70). The incidence of acute renal dysfunction was 14.8% 
      (four out of 27 cases), all classified as "injury" according to RIFLE criteria. 
      The incidence of hyperpigmentation was 59.3%. Conclusion: Polymyxin B is a viable 
      treatment option for granulocytopenia patients with refractory gram-negative 
      bacterial bloodstream infections.
FAU - Zhou, M
AU  - Zhou M
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Kang, H Z
AU  - Kang HZ
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Gu, C Y
AU  - Gu CY
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Liu, Y J
AU  - Liu YJ
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Wang, Y
AU  - Wang Y
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Miao, M
AU  - Miao M
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Fu, J H
AU  - Fu JH
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Tang, X W
AU  - Tang XW
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Qiu, H Y
AU  - Qiu HY
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Fu, C C
AU  - Fu CC
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Jin, Z M
AU  - Jin ZM
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Li, C X
AU  - Li CX
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Chen, S N
AU  - Chen SN
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Sun, A N
AU  - Sun AN
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Wu, D P
AU  - Wu DP
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
FAU - Han, Y
AU  - Han Y
AD  - The First Affiliated Hospital of Soochow University, Jiangsu Institute of 
      Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 
      National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - J2VZ07J96K (Polymyxin B)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - Polymyxin B/therapeutic use/adverse effects
MH  - Retrospective Studies
MH  - *Gram-Negative Bacterial Infections/drug therapy/complications
MH  - Fever/chemically induced/drug therapy
MH  - *Sepsis/drug therapy
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Bacteremia/drug therapy/complications
PMC - PMC10450549
OTO - NOTNLM
OT  - Bloodstream infection
OT  - Neutropenia
OT  - Polymyxin B
OT  - Refractory Gram-negative bacterium
COIS- 利益冲突 本文所有作者声明不存在利益冲突
EDAT- 2023/08/08 00:42
MHDA- 2023/08/09 06:43
PMCR- 2023/06/01
CRDT- 2023/08/07 22:04
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/08/08 00:42 [pubmed]
PHST- 2023/08/07 22:04 [entrez]
PHST- 2023/06/01 00:00 [pmc-release]
AID - cjh-44-06-484 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2023.06.007 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):484-489. doi: 
      10.3760/cma.j.issn.0253-2727.2023.06.007.